Features
Endophthalmitis Then and Now
More than a century of innovation has transformed how endophthalmitis is prevented, diagnosed, and treated.
By Landon J. Rohowetz, MD, Patrick C. Staropoli, MD, Stephen G. Schwartz, MD, MBA, et al.
The Clinical Trial Team Gets an AI Teammate
Artificial intelligence may bring a paradigm shift by dramatically improving the efficiency of clinical trial sites.
By Mark R. Barakat, MD, Ram Yalamanchili
Stem Cell Therapies for Retinal Degenerations
This approach holds promise for preserving and restoring vision in AMD, RP, and beyond.
By Noah M. Heaps, BS, Maximilian D. Kong, BS, Aykut Demirkol, MD, et al.
Heads-Up Surgical Display Systems Come Into Focus
Digital platforms are transforming ergonomics, visualization, and education in retina.
By Shivesh H. Shah, BA, John B. Miller, MD
Web Exclusives
Microbots as a Potential Treatment for Vitreous Hemorrhage
A Conversation with Louis William Rogowski, PhD, and Min Jun Kim, PhD.
By Jim Gallagher, senior managing editor
Departments
Upfront: Technology and the Retina
By Diana V. Do, MD
Coding Q&A: Proper Documentation for Diagnostic Tests
Follow CMS guidelines to ensure compliance and minimize claim denials when ordering diagnostic tests.
By Elizabeth Cifers, MBA, MSW, CHC, CPC
Clinical Trial Update May 2025
Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.
News
FDA Shares Insights on Treatment Approvals, Clinical Trial Design
Dr. William Boyd, head of the FDA’s ophthalmology division, discussed his agency and answered questions related to retinal trials at RWC 2025.
By Jim Gallagher, senior managing editor
Pooled Data on NT-501 Presented at RWC
Neurotech's Encelto is the first FDA-approved therapy for patients with macular telangiectasia.
By W. Lloyd Clark, MD
Fas Inhibition Shows Neuroprotective Benefit for GA
In a phase 1b study, eyes treated with ONL1204 demonstrated reductions in geographic atrophy lesion growth.
By Jim Gallagher, senior managing editor
PRISM Trial Update Presented at RWC
4D-150 is designed for single, low-dose intravitreal delivery for transgene expression from the retina.
By Mark R. Barakat, MD
Current Pipeline for Noninfectious Uveitis
Systemic and local treatments being investigated in clinical trials include TYK2/JAK1 modulators and IL-6 inhibitors.
By Jim Gallagher, senior managing editor
Reducing the Risk of Radiation Retinopathy
New strategies aim to preserve vision after uveal melanoma treatment.
By Jim Gallagher, senior managing editor
AI Tools Can Help Low-Vision Patients
Mitul Mehta, MD, discusses how voice-guided apps and wearable devices help patients read, recognize faces, and navigate.
By Mitul Mehta, MD, MS, FASRS
Real-World nAMD Treatment Patterns Reveal Cost of Switching
Analysis of Medicare claims show increases in drug-related expenditures after initial low-cost therapy.
By Jim Gallagher, senior managing editor
EYP-1901 Shows Durable, Sustained Efficacy in VERONA
Carl Regillo, MD, presented new data from the VERONA phase 2 clinical trial of EYP-1901 for DME at Retina World Congress.
By Carl D. Regillo, MD, FACS
Efficacy Data on Eye Drop for DME Presented at RWC
Statistically significant retinal thickness reductions and BVCA gains were maintained to 12 weeks.
By Jim Gallagher, senior managing editor
Who Stops GA Therapy—and Why
An analysis of patients receiving complement inhibitors finds baseline wet AMD and poor vision linked to treatment discontinuation.
By Jim Gallagher, senior managing editor
A Shift in Strategy for Ocular Melanoma
Timothy Murray, MD, shares 5-year data from a large series of small choroidal melanomas that indicates early treatment improves survival and preserves vision.
By Timothy G. Murray, MD, MBA, FACS
A Suprachoroidal Route to Retinal Therapy
Suprachoroidal gene delivery emerges as a promising alternative to subretinal or intravitreal injections.
By Jim Gallagher, senior managing editor
Migaldendranib May Move the Needle in AMD, DME
Michael A. Singer, MD, shares early phase 2 data supporting D-4517.2 as a safe and effective subcutaneous therapy that reduces injection burden and preserves vision.
By Michael A. Singer, MD
New Hope for Stargardt Patients
Six companies are actively developing therapies for Stargardt disease that aim to slow vision loss through various mechanisms.
By Jim Gallagher, senior managing editor
EYP-1901 Shows 9-Month Disease Control in NPDR Patients
Despite missing the 12-month primary endpoint in PAVIA, the implant demonstrated early efficacy, guiding design for a planned phase 3 trial.
By Jim Gallagher, senior managing editor
Isarna Reports Antisense Therapy Trial Data
The BETTER trial results support further testing of the experimental TGF-β2-blocking drug in retinal diseases, including wet AMD and DME.
Real-World Eylea HD Data Presented at ARVO
Initial data from nearly 40,000 patients demonstrate early visual improvements and reduced injection frequency.
By Jim Gallagher, senior managing editor
New Data From ARVO Support Efficacy of Axitinib in NPDR
Results support further investigation of OTX-TKI as a long-acting treatment.
AAVantgarde Shares Clinical Data at ARVO 2025
Findings support continued development of gene therapies for Usher syndrome and Stargardt disease.
Optigo Wins People’s Choice Award at Eyecelerator 2025
At ARVO, the company presented preclinical data supporting the potential for 6-month dosing intervals in nAMD, DME, and RVO.
Real-World Data Supports Uveal Melanoma Test Combo
New data presented at ARVO 2025 confirms that adding PRAME status enhances the DecisionDx-UM test’s ability to predict metastasis.
Beacon Reports Interim Data on XLRP Therapy
At ARVO 2025, data presented from the DAWN phase 2 trial of the gene therapy showed promising improvements in visual function across several key measures.
Atsena Reports LIGHTHOUSE data at ARVO
Gene therapy ATSN-201 shows good safety, efficacy signs in first part of the trial.
Supported Content
Phase 2 Data From BETTER Trial for Retinal Fibrosis
Marion Munk, MD, PhD, FEBO, discusses the current trials for ISTH0036.
By Marion R. Munk, MD, PhD, FEBO, Michael A. Singer, MD